HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciences, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Neutral rating for Ventyx Biosciences (NASDAQ:VTYX) and maintained a price target of $6.

September 23, 2024 | 5:23 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated a Neutral rating for Ventyx Biosciences with a maintained price target of $6, indicating no expected short-term price movement.
The reiteration of a Neutral rating and maintenance of the $6 price target by HC Wainwright & Co. suggests that the analyst does not foresee significant short-term changes in Ventyx Biosciences' stock price. This indicates stability in the company's current valuation.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100